TrialEuropean journal of cancer (Oxford, England : 1990)2022

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.

Guilhem Roubaud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.